medigraphic.com
Anales de Otorrinolaringología Mexicana

2007, Number 4

<< Back Next >>

Otorrinolaringología 2007; 52 (4)

Abductor spasmodic dysphonia treatment with bilateral application of botulinum type A toxine in tiroaritenoideal muscles

Pérez TMC, Cruz HJ

Language: Spanish
References: 19
Page: 141-146
PDF size: 177.45 Kb.


ABSTRACT

Background: The adductor spasmodic dysphonia is caused by a neurological disorder that induces spasms in the vocal chords and it generates the sustained abnormal muscular activity. Its treatment with botulinum toxin has given good results.
Objective: To report the experiences, techniques and results of the treatment of six patients with diagnosis of adductor spasmodic dysphonia, to those who were applied injections of botulinum toxin type A.
Patients and Method: Six patients with adductor spasmodic dysphonia diagnosis received bilateral injections of botulinum toxin in thyroarytenoid muscles. They were examined by stroboscopic analyses before and after the treatment.
Results: Treatment with botulinum toxin type A resulted in significant improvement in voice function. Most of the patients (66.6%) were women. Their mean age was 51 years. Response to the injection lasted from 1 to 5 days, length of effect was from 3 to 12 weeks. There were no airway or infectious complications from percutaneous technique. There were no cases of postinjection aspiration. Mayor adverse reaction included swallowing problems.
Conclusions: Botulinum toxin is still a treatment alternative to spasmodic dysphonia, due to it tested results with less side effects. Its disadvantages are short-term effect and relatively high cost.


REFERENCES

  1. Cyrus C, Bielamowicz S, Evans F, Ludlow C. Adductor muscle activity abnormalities in abductor spasmodic dysphonia. Otolayringol Head Neck Surg 2001;124:23-30.

  2. Blitzer A, Brin M, Stewart C. Botulinum toxin management of spasmodic dysphonia (laringeal dystonia): a 12 year experience in more than 900 patients. Laryngoscope 1998;108:1435-41.

  3. Kobayashi T, Niimi S, Kumada M, Kosaki H, Hirose H. Botulinum toxin treatment for spasmodic dysphonia. Acta Otolaryngol 1993;504(Suppl):155-7.

  4. Remacle C, Lawson G. Trastornos funcionales de la laringe. Encyclopédie Médico-Chirurgicale 2000;-E-20-690-A-10.

  5. Bielamowicz S, Bidus K, Squire S, Ludlow C. Assessment of posterior cricoarytenoid botulinum toxin injections in patients whit abductor spasmodic dysphonia. Ann Otol Rhynol Laryngol 2001;110:406-12.

  6. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 2001;111:218-26.

  7. Schönweiler R, Wohlfarth K, Dengler R, Ptok M. Supraglottal injection of botulinum toxin tipe A in adductor type spasmodic dysfhonia with both intrinsic and extrinsic hyperfunction. Laryngoscope 1998;108:55-63.

  8. Jackson-Menaldi M. La voz patológica. Buenos Aires: Panamericana, 2002.

  9. Green D, Berke G. Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. Ann Otol Rhinol Laryngol 1992;101:883-7.

  10. Inagi K, Ford C, Rodriguez SA, Heisey D. Transoral electromyographic recordings in botulinum toxin-injected rat larynges. Ann Otol Rhinol Laryngol 1997;106:956-64.

  11. Davison B, Ludlow C. Long term effects of botulinum toxin injections in spasmodic dysphonia. Ann Otol Rhinol Laryngol 1996;105(1):33-42.

  12. 12 Langeveld T, Houtman E, Briaire J, Rossum M, et al. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment. Ann Otol Rhinol Laryngol 2001;110:627-34.

  13. Elaina F, Zimbler M, Biller H, Wu B, Sanders I. Quantitative mapping of the botulinum toxin injections in the thyroarytenoid muscule. Ann Otol Rhinol Laryngol 1992;101:888-92.

  14. Castellanos PF, Gates GA, Esselman G, Song F, et al. Anatomic considerations in botulinum toxin type A therapy for spasmodic dysphonia. Laryngoscope 1994;104(6 pt):656-62.

  15. Liu TC, Irish JC, Adams SG, Durkin LC, Hunt EJ. Prospective study of patients subjective responses to botulinum toxin for spasmodic dysphonia. J Otolaryngol 1996;25(2):66-74.

  16. Langeveld TP, Drost HA, Baatenburg de Jong RJ. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 1998;107(4):280-4.

  17. Zwirner P, Murry T, Woodson GE. A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia. Eur Arch Otorhinolaryngol 1993;250(5):271-6.

  18. Grillone GA, Blitzer A, Brin MF, Annino DJ, Saint- Hilaire MH. Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A. Laryngoscope 1994;104(1pt1):30-2.

  19. Sulica L, Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of adductor spasmodic dysphonia after failer recurrent laryngeal nerve section. Ann Otol Rhinol Laryngol 2003;112(6):499-505.




2020     |     www.medigraphic.com